CG OncologyCGON
CGON
About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees: 113
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
450% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $3.7M
164% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 28
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
13% more capital invested
Capital invested by funds: $1.74B [Q1] → $1.96B (+$228M) [Q2]
11% more funds holding
Funds holding: 142 [Q1] → 158 (+16) [Q2]
6.26% more ownership
Funds ownership: 92.84% [Q1] → 99.1% (+6.26%) [Q2]
10% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
108%
upside
Avg. target
$55
115%
upside
High target
$56
120%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Kelsey Goodwin | 116%upside $55 | Overweight Initiated | 19 Aug 2025 |
RBC Capital Leonid Timashev | 109%upside $53 | Outperform Maintained | 16 Jul 2025 |
Morgan Stanley Jeffrey Hung | 120%upside $56 | Overweight Maintained | 17 Jun 2025 |
Financial journalist opinion
Neutral
The Motley Fool
2 weeks ago
Cg Oncology (CGON) Q2 Loss Widens 93%
Cg Oncology (CGON) Q2 Loss Widens 93%
Neutral
GlobeNewsWire
2 weeks ago
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - - Announced unanimous verdict that CG Oncology owes no future royalties or other payments to ANI Pharmaceuticals - IRVINE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.
Positive
Seeking Alpha
2 months ago
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.
Neutral
GlobeNewsWire
2 months ago
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Positive
Zacks Investment Research
3 months ago
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Negative
Zacks Investment Research
3 months ago
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.
Negative
Zacks Investment Research
3 months ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
3 months ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Benzinga
3 months ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Charts implemented using Lightweight Charts™